Ideaya Biosciences, Inc. (IDYA) Stock Price & Analysis
Ideaya Biosciences, Inc. (IDYA) fell 10.83% to USD 28.07 as of June 10, 2026 at 00:50 UTC, according to Nexqual real-time market data.
IDYA last closed at USD 31.48; the session ranged USD 27.86–31.95 on volume of 4,209,576 shares. Market capitalization is $2.50B, with a 52-week range of USD 20.5–39.28 (NMS). Source: Nexqual, June 10, 2026 at 00:50 UTC.
Key Statistics (as of June 10, 2026 at 00:50 UTC)
| Price | USD 28.07 |
|---|---|
| Change | ▼ 10.83% (down) |
| Previous Close | USD 31.48 |
| Open | USD 30.32 |
| Day Range | USD 27.86 – 31.95 |
| 52-Week Range | USD 20.5 – 39.28 |
| Volume | 4,209,576 shares |
| Market Cap | $2.50B |
| Exchange | NMS |
Technical Analysis (IDYA)
Nexqual's technical model rates IDYA "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:50 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.42 (neutral) |
| vs SMA50 | Below (USD 30.03) |
| MACD | -0.19 (negative) |
Analyst Ratings (IDYA)
Wall Street analysts rate IDYA "Strong Buy" based on 16 analysts, with a mean price target of USD 51.69 (range USD 36–66), per Nexqual as of June 10, 2026 at 00:50 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 51.69 |
| High Target | USD 66 |
| Low Target | USD 36 |
| Buy / Hold / Sell | 16 / 2 / 0 |
Earnings (IDYA)
| Next Earnings Date | 2026-05-05 |
|---|---|
| EPS Estimate | USD -1.07 |
| Revenue Estimate | $7.25M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.11 vs est -0.98 ▼ miss |
| 2025-12-31 | USD -0.94 vs est -0.95 ▲ beat |
| 2025-09-30 | USD 1.33 vs est -0.55 ▲ beat |
| 2025-06-30 | USD -0.88 vs est -0.79 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financials & Fundamentals (IDYA)
| Total Revenue | $225.27M |
|---|---|
| Gross Margin | -50.73% |
| Operating Margin | -1654.63% |
| Profit Margin | -62.17% |
| ROE | -14.28% |
| Debt / Equity | 3.05 |
| Current Ratio | 10.74 |
| Total Cash | $671.20M |
| Total Debt | $28.60M |
| Free Cash Flow | $-57.25M |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financial Health Score (IDYA)
Nexqual rates Ideaya Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:50 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $671M cash vs $29M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$57M, burning cash |
| Efficiency | Critical — ROE -14%, ROA -10.8% |
Ownership (IDYA)
| Insider Ownership | +2.41% |
|---|---|
| Institutional Ownership | +110.07% |
| Shares Outstanding | 89.05M |
| Float | 87.01M |
| Short % of Float | +15.23% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Leadership (IDYA)
Ideaya Biosciences, Inc. is led by Yujiro S. Hata (age 51), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 00:50 UTC.
| Founder, President, CEO & Director | Yujiro S. Hata (age 51) |
|---|---|
| Chief Financial Officer | Joshua Bleharski (age 50) |
| Chief Scientific Officer | Michael A. White (age 60) |
| Chief Technology Officer | Paul A. Barsanti |
| Senior Vice President of Medical Writing & Project Management | Mick O'Quigley |
Major Backers & Investors (IDYA)
Notable institutional backers of Ideaya Biosciences, Inc. include FMR, LLC, Janus Henderson Group PLC, Fidelity, according to Nexqual as of June 10, 2026 at 00:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.99% |
| Janus Henderson Group PLC | 8.27% |
| Fidelity | 7.48% |
| Federated Hermes, Inc. | 7.11% |
| Capital Group | 5.88% |
| SmallCap World Fund Inc | 5.33% |
| Baker Bros. Advisors, LP | 4.49% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.87% |
| Vanguard Group | 8.4% |
| State Street | 6.37% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
From Ideaya Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
- The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
- In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
- The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| BCYC | Bicycle Therapeutics plc | USD 4.17 | ▼ 0.71% |
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
| NUVL | Nuvalent, Inc. | USD 123.25 | ▲ 35.51% |
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:50 UTC. This page is informational and not investment advice.